TDC
ATRS

Thompson Davis & Co’s Antares Pharma, Inc. ATRS Stock Holding History

Thompson Davis & Co’s Portfolio ATRS Stock Details ATRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-112,768
Closed -$365K – 1154
2017
Q3 		$365K Sell
112,768
-79,966
-41% -$247K 0.65% 25
2017
Q2 		$621K Buy
192,734
+124,348
+182% +$352K 1% 17
2017
Q1 		$194K Buy
68,386
+30,560
+81% +$73.5K 0.28% 83
2016
Q4 		$88K Buy
37,826
+23,232
+159% +$44.2K 0.15% 158
2016
Q3 		$25K Sell
14,594
-4,827
-25% -$5.91K 0.04% 403
2016
Q2 		$20K Buy
+19,421
New +$18.8K 0.03% 475
2015
Q1 		– Sell
-7,000
Closed -$18K – 1288
2014
Q4 		$18K Hold
7,000
– – 0.02% 554
2014
Q3 		$13K Sell
7,000
-29,500
-81% -$64.3K 0.02% 617
2014
Q2 		$97K Hold
36,500
– – 0.14% 180
2014
Q1 		$128K Hold
36,500
– – 0.21% 120
2013
Q4 		$163K Buy
+36,500
New +$149K 0.25% 96

Other funds holding ATRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Thompson Davis & Co's ATRS Position: Q4 2017 in Review

Thompson Davis & Co sold out of Antares Pharma, Inc. (ATRS) in Q4 2017, closing a stake of 112,768 shares — an estimated $365K sold.

Thompson Davis & Co first reported a position in ATRS in Q4 2013 and held it in 11 quarters. The position peaked at $621K in Q2 2017. 110 funds tracked by Wall St. Rank hold ATRS as of Q4 2017.

  • Thompson Davis & Co reported no remaining Antares Pharma, Inc. position as of Q4 2017 after selling out during the quarter.
  • Thompson Davis & Co sold 112,768 Antares Pharma, Inc. shares in Q4 2017, an estimated $365K.
  • Thompson Davis & Co first reported a position in Antares Pharma, Inc. in Q4 2013 and held it in 11 quarters.
  • Thompson Davis & Co's Antares Pharma, Inc. position peaked at $621K in Q2 2017.
  • 110 funds tracked by Wall St. Rank held Antares Pharma, Inc. as of Q4 2017.

Based on Thompson Davis & Co's 13F filing for Q4 2017, filed 5 Feb 2018.